Head-to-head evidence
Olanzapine (Zyprexa Relprevv) vs Paliperidone palmitate (Invega Trinza)
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Schizophrenia
Shared mechanism: Dopamine D2 and serotonin 5-HT2A receptors (antagonist) · full Schizophrenia pipeline
Olanzapine (Zyprexa Relprevv)
Marketed by Cheplapharm Arzneimittel GmbH and partners
NCT00088478 · Phase 3 · completed
This was a randomized, double-blind, placebo-controlled trial of 402 patients. All three tested doses of the long-acting olanzapine injection produced a significantly greater reduction in psychiatric symptom severity (PANSS) than placebo.
Next expected readout: December 2027 · NCT07047651 (registry estimate)
Paliperidone palmitate (Invega Trinza)
Marketed by Johnson & Johnson
NCT02713282 · Phase 3 · completed
This was a single-group, open-label study without randomization or a comparator arm, so it could not directly compare the 3-month formulation with placebo or another treatment. Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Olanzapine (Zyprexa Relprevv)'s landscape · Paliperidone palmitate (Invega Trinza)'s landscape